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Background and Purpose: GPCRs can signal through both G proteins and β-arrestin2.
For the μ-opioid receptor, early experimental evidence from a single study suggested
that G protein signalling mediates analgesia, whereas β-arrestin2 signalling mediates
respiratory depression and constipation. Consequently, for more than a decade,
much research effort has been focused on developing biased μ-opioid agonists that
preferentially target G protein signalling over β-arrestin signalling, as it was believed
that such drugs would be analgesics devoid of respiratory depressant activity. How-
ever, the prototypical compounds that have been developed based on this concept
have so far failed in clinical and preclinical development.
Experimental Approach: The present study was set up to re-examine opioid-induced
respiratory depression in β-arrestin2 knockout mice. To this end, a consortium was
formed consisting of three different laboratories located in different countries to
evaluate independently opioid-induced respiratory depression.
Key Results: Our consensus results unequivocally demonstrate that the prototypical
μ-opioid agonist morphine (3.75–100 mgkg−1 s.c. or 3–30 mgkg−1 i.p.) as well as the
potent opioid fentanyl (0.05–0.35 mgkg−1 s.c.) do indeed induce respiratory depres-
sion and constipation in β-arrestin2 knockout mice in a dose-dependent manner
indistinguishable from that observed in wild-type mice.
Conclusion and Implications: Our findings do not support the original suggestion that
β-arrestin2 signalling plays a key role in opioid-induced respiratory depression and
call into question the concept of developing G protein-biased μ-opioid receptor ago-
nists as a strategy for the development of safer opioid analgesic drugs.
Abbreviation: βarr2−/−, β-arrestin2 knockout.
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1 | INTRODUCTION
Regulatory β-arrestin proteins, downstream of GPCRs, are widely
understood to mediate receptor desensitisation. Binding of β-
arrestins to phosphorylated GPCRs is also believed to trigger a sec-
ond wave of G protein-independent signalling (Reiter, Ahn,
Shukla, & Lefkowitz, 2012). The discovery of ligands that preferen-
tially stimulate G protein or β-arrestin2 signalling has led to the
concept of “biased agonism” or “functional selectivity.” However,
for most GPCRs, it is still unclear which in vivo physiological
responses are mediated by G protein signalling and which
responses are mediated by β-arrestin2 signalling. Nevertheless,
there is currently a growing interest in the development of func-
tionally selective GPCR ligands facilitated by hopes of producing
more effective drugs with reduced side effects (Wacker, Stevens, &
Roth, 2017). In the development of new opioid analgesic drugs, a
key driving force was a study published in 2005 on β-arrestin2
knockout mice that reported enhanced and prolonged analgesic
effects after morphine application, presumably due to decreased
receptor desensitisation, and reduced respiratory depressant and
constipatory effects (Raehal, Walker, & Bohn, 2005). These results
led to the novel concept that opioid analgesia is mediated via G
protein signalling, while respiratory depression and constipation are
mediated predominantly via β-arrestin-dependent signalling path-
ways. Despite much research effort devoted towards the develop-
ment of novel G protein-biased μ-opioid agonists, this hypothesis
has not been verified thus far. The first prototypical compound
oliceridine (TRV130) recently completed phase 3 clinical studies
but failed to demonstrate superiority to morphine in terms of
respiratory safety burden in humans (Hertz, 2018). Another poten-
tially G protein-biased μ-opioid agonist, PZM21, was discovered
using a structure-based approach (Manglik et al., 2016). Although
initially reported to produce fewer side effects, a later study clearly
demonstrated that PZM21 still produced pronounced respiratory
depression in mice (Hill et al., 2018).
Moreover, the biased agonism concept was recently tested using
a different approach. By generating knock-in mice with a series of
carboxyl-terminal S/T to alanine mutations that are increasingly
unable to recruit regulatory β-arrestin proteins, a novel model was
created that allows genetic dissection of signalling bias at the
μ-receptor level (Kliewer et al., 2019). As phosphorylation-deficient
receptors signal via G proteins for prolonged periods without appar-
ent desensitisation but at the same time fail to recruit β-arrestin pro-
teins, these mutants can be viewed as G protein-biased μ-opioid
receptors. Mice expressing phosphorylation-deficient, G protein-
biased μ-opioid receptors showed enhanced analgesia in response to
morphine, but, contrary to prediction, they still exhibited respiratory
depression and other opioid-induced side effects such as
constipation.
Given these contradictory results, we formed a consortium con-
sisting of three different laboratories to re-examine opioid-induced
respiratory depression in β-arrestin2 knockout mice in a systematic
manner.
2 | METHODS
2.1 | Jena, Germany
2.1.1 | Animals
β-Arrestin2 knockout mice strain B6.129-Arrb2tm1Rjl/J (βarr2−/−,
RRID:IMSR_JAX:011130) were obtained from JAX™/Charles River
Laboratories (DE). Mice were genotyped by PCR analysis of genomic
tail-biopsy DNA using the following primers: 50-GCTAAAG
CGCATGCTCCAGA-30 , 50-ACAGGGTCCACTTTGTCCA-30, and 50-
GATCAAAGCCCTCGATGATC-30. β-Arrestin2 knockout mice were
backcrossed over seven generations to wild-type control JAX™
C57BL/6J (RRID:IMSR_JAX:000664) mice from Charles River Labora-
tories (DE), which were also used for breeding of the knockout strain
and as controls in all experiments. Mice were housed two to six per
cage under a 12-hr light–dark cycle (lights on at 6 a.m.) and ventilated
at constant temperature of 21–23C with ad libitum access to food
and water. In all behavioural experiments, we used male mice aged
8–26 weeks and weighing 21–30 g. Studies were performed in paral-
lel such that age-matched mice received the same drug treatment at
the same time. To avoid daytime effects, studies were carried out in
small cohorts of mice (n = 6) at a time.
2.1.2 | Drugs
Drug doses were calculated according to the active component of the
salt and were freshly prepared prior to use and diluted in PBS for
injections. Morphine sulphate (3.75–52.5 mgkg−1; Hameln Inc.,
Hameln, Germany) and fentanyl citrate (0.05–3 mgkg−1;
Rotexmedica, Trittau, Germany) were injected subcutaneously in
lightly restrained, unanaesthetised mice at a volume of 10 μlg−1 body
weight.
What is already known
• Data suggests that μ-opioid analgesia is via G protein;
respiratory depression/constipation is via β-arrestin2
signalling.
• However, compounds based on the concept of biased
agonism failed in clinical and preclinical development.
What this study adds
• μ-Opioid agonists morphine and fentanyl induce respira-
tory depression and constipation in β-arrestin2 knockout
mice.
What is the clinical significance
• These results question G protein-biased agonists as a
strategy for safer opioid analgesic drugs.
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2.1.3 | Mouse respiration experiments
In the respiration studies, one experimenter and a dedicated assis-
tant performed all in vivo drug administrations and behavioural test-
ing. Animals were assigned to groups randomly before testing. Mice
were excluded from the study if they displayed any bodily injuries
from aggressions with cage mates. The experimenter was blinded to
treatment and/or genotype throughout the course of behavioural
testing. All drugs were given to the experimenter in coded vials and
decoded after completion of the experiment. All testing was con-
ducted between 7 a.m. and 4 p.m. in an isolated, temperature- and
light-controlled room. Mice were acclimated to the facility for at
least 2 weeks before testing. Only the experimenter and assistant
had free access to the room and entered the room 30 min before
commencement of testing to eliminate potential olfactory-induced
changes in nociception. All data from wild-type and β-arrestin2
knockout mice were generated in parallel with testing of
phosphorylation-deficient μ-opioid receptor mice (S375A, 10S/T-A
and 11S/T-A) published in Kliewer et al. (2019). Therefore, data
from wild-type mice shown in this paper were previously published.
Respiratory rates were recorded with a nose-out plethysmography
system (Hugo Sachs Elektronik–Harvard Apparatus GmbH, DE). Indi-
vidual unanaesthetised mice were placed in a restrainer with their
nose exposed through a close-fitting hole in the membrane. A
pneumotachograph was connected to the chamber equipped with a
differential low-pressure transducer (transducer DLP2.5, Hugo Sachs
Elektronik–Harvard Apparatus GmbH). Volume changes were cali-
brated by injecting known amounts of air into the chamber. Ana-
logue pressure signals were digitised for later analysis (Levitt,
Hunnicutt, Knopp, Williams, & Bissonnette, 2013). Mice were accli-
mated to the test chamber, and baseline respiratory parameters
were recorded for 30 min. The 30-min test was then repeated
15 min (fentanyl) or 30 min (morphine) after injection of different
doses of fentanyl or morphine as indicated. Data were analysed in
Pulmodyn® W Software (Hugo Sachs Elektronik–Harvard Apparatus
GmbH).
2.1.4 | Accumulated faecal boli quantification
Mice were subcutaneously injected with vehicle or different doses of
morphine or fentanyl as indicated and individually placed into small
Plexiglas boxes (26.5 cm × 20.5 cm × 14 cm) lined with filter paper.
Faecal boli were collected and weighed every hour for 3 hr (fentanyl)
or 5 hr (morphine; Kliewer et al., 2019; Raehal et al., 2005).
2.2 | Sydney, Australia
2.2.1 | Animals
β-Arrestin2 knockout mice were kindly provided by Drs Lefkowitz and
Caron (Duke University; Bohn, Gainetdinov, Lin, Lefkowitz, & Caron,
2000) and have been maintained as heterozygotes. Mice were
genotyped by PCR analysis using the following primers: Forward
1 (50-TCTTCAAGAAGTCGAGCCCT-30), Forward 2 (50-GCTAAA-
GCGCATGCTCCAGA-30), and Reverse (50-ACAGGGTCCACTT-
TGTCCA-30). The knockout line was backcrossed with freshly
purchased C57BL/6J wild-type mice (The Animal Resources Centre,
Perth, Western Australia) on at least four separate occasions since
2010 followed by extensive heterozygote X heterozygote mattings.
β-Arrestin2 knockout mice were offspring from a mix of heterozygote
and homozygote crosses. Wild types were offspring from within the
β-arrestin2 knockout colony. Animals were housed no more than six
per cage under a 12-hr light–dark cycle (lights on at 6 a.m.) and
ventilated at constant temperature of 21–23C with ad libitum
access to food and water. We used male mice between the ages of
6 and 18 weeks, with each experimental group comprising six to
11 mice per genotype per dose. Each animal was used for only a
single dose.
2.2.2 | Drugs
Doses of morphine hydrochloride (3–100 mgkg−1; GlaxoSmithKline,
Australia) calculated as the active component of the salt were
dissolved in saline and injected subcutaneously to lightly
restrained, unanaesthetised mice at a maximum volume of 200 μl per
mouse.
2.2.3 | Mouse respiration experiments
A single experimenter carried out all studies, and animals were ran-
domly acclimatised to handling, the testing room and equipment
before experimentation. Morphine-induced changes to respiratory
function were assessed on awake, freely moving mice using two paral-
lel whole-body plethysmography chambers connected to a pressure
transducer with the accompanying controller and software (Buxco,
DSI Instruments). A constant flow, calibrated before each experiment,
of room air into each chamber is maintained by the system. Mice were
pre-acclimatised to the chamber for 20–25 min on the day before the
experiment and were shielded from view of the other chamber. On
the day of experimentation, animals were acclimatised for 25 min, of
which the final 5 min were taken as a baseline. Mice were removed
from the chamber for injection of morphine hydrochloride within a
2-min window. Mice were returned to the chamber and respiratory
function was assessed for the next 3 hr. Respiratory rate was deter-
mined by the system software (Buxco FinePointe, DSI Instruments)
and averaged in 5-min intervals. For time course analyses, parameters
were normalised to the pre-drug baseline as 100%. Peak drug effect
on respiratory frequency was taken as the 5-min period with the
slowest breathing in the hour following each injection. Sleeping mice
were excluded for that period. Data were reanalysed completely blind
to the genotype by a separate experimenter familiar with the
technique.
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2.3 | Bristol, United Kingdom
2.3.1 | Animals
Adult β-arrestin2 knockout mice strain B6.129-Arrb2tm1Rjl/J
(βarr2−/−) and wild types from within the β-arrestin2 knockout
colony were kindly provided by Dr Stefan Schulz (Jena University,
Germany). Animals were housed up to four per cage under a 12-hr
light–dark cycle (lights on at 8 a.m.) and ventilated at constant
temperature of 21–23C with ad libitum access to food and water.
We used male mice weighing 21–30 g, with each experimental group
comprising six mice per genotype. Studies were performed in parallel
such that β-arrestin2 knockout mice and wild-type mice received the
same drug treatment at the same time.
2.3.2 | Drugs
Doses of morphine hydrochloride (1–10 mgkg−1; MacFarlan Smith,
UK) calculated as weight of the salt were dissolved in saline and
administrated intraperitoneally to lightly restrained, unanaesthetised
mice in a volume of 0.1 ml. A single experimenter performed all in vivo
drug administrations and respiration monitoring. Mice were assigned
to groups randomly before testing. The experimenter was blinded to
treatment and/or genotype throughout the course of the experiment.
All drugs were given to the experimenter in coded vials and decoded
after data analysis had been performed.
2.3.3 | Mouse respiration experiments
Experiments were conducted during the dark cycle between 8 a.m.
and 8 p.m. using a red light. Mice were habituated to handling and
the plethysmograph chambers prior to experimentation. Respiration
was measured as previously described (Hill et al., 2016, 2018) in
freely moving mice using whole-body plethysmography chambers
(EMKA Technologies, Paris, France) supplied with a 5% CO2 in air mix-
ture (BOC Gas Supplies, Manchester, UK). Rate and volume of respira-
tion were recorded and averaged over 5-min periods. Breathing 5%
CO2 in air increases min volume but does not induce stress in mice
(Hill et al., 2016). Mice were habituated to plethysmograph chambers
for 30 min on the day before the experiment. On the day of the
experiment, baseline values of respiratory rate were recorded for
20 min, and then mice were removed from the chamber for 2 min for
morphine injection after which respiration was measured for a further
40 min.
2.4 | Animal experiments
The animal experiments conducted at Jena University Hospital were
performed in accordance with the Thuringian state authorities, com-
plied with the European Commission regulations for the care and use
of laboratory animals, and were in accordance with the National Insti-
tutes of Health Guide for the Care and Use of Laboratory Animals.
Those conducted at University of Sydney were performed under the
guidelines of the Australian code of practice for the care and use of
animals for scientific purposes (National Health and Medical Research
Council, Australia, 7th Edition) and were approved by the University
of Sydney Animal Ethics Committee. Those performed at the Univer-
sity of Bristol were conducted in accordance with the UK Animals
(Scientific Procedures) Act 1986 and the European Communities
Council Directive (2010/63/EU) and were approved by the University
of Bristol Animal Welfare and Ethics Review Board. Animal studies
are reported in compliance with the ARRIVE guidelines (Kilkenny,
Browne, Cuthill, Emerson, & Altman, 2010) and with the recommen-
dations made by the British Journal of Pharmacology.
2.5 | Western blot analysis
Mice were anesthetised with isoflurane and killed by cervical disloca-
tion, and brains were quickly dissected excluding the cerebellum. The
remaining brain samples were immediately frozen in liquid nitrogen.
Brains were transferred to ice-cold detergent buffer (50-mM Tris–
HCl, pH 7.4, 150-mM NaCl, 5-mM EDTA, 10-mM NaF, 10-mM dis-
odium pyrophosphate, 1% Nonidet P-40, 0.5% sodium deoxycholate,
0.1% SDS, containing protease and phosphatase inhibitors),
homogenised, and centrifuged at 14,000× g for 30 min at 4C. The
supernatant was added with SDS sample buffer, incubated for 5 min
at 95C, and then resolved on 8% SDS-polyacrylamide gels. After
electroblotting, membranes were incubated with the anti-β-arrestin2
(#3857, Cell Signaling, RRID:AB_2258681), anti-β-arrestin1 (ab32099,
abcam, RRID:AB_722896) antisera followed by detection using an
enhanced chemiluminescence detection system (Amersham, Braun-
schweig, Germany). Blots were subsequently stripped and reprobed
with anti-actin (sc-47778, Santa Cruz Biotechnology, RRID:
AB_626632) to confirm equal loading of the gels. Protein bands on
western blots were exposed to X-ray film. Films exposed in the linear
range were then densitised using ImageJ 1.37v (RRID:SCR_003070).
The Immuno-related procedures used comply with the recommenda-
tions made by the British Journal of Pharmacology (Alexander et al.,
2018).
2.6 | Experimental design and data analysis
Data from previous experiments where respiratory depression or
antinociception was measured following acute opioid administration
in naïve mice were subjected to post hoc power analyses using
G*Power (version 3.1.9, RRID:SCR_013726). Our calculations indi-
cated that in acute respiration experiments, n = 6 for each individual
group would produce a significant result if an actual effect occurred.
The results for each experiment were expressed as the
means ± SEM. In the experiments performed in Germany, a cut-off for
respiratory rate was set at 60 and 360 breathsmin−1 for baseline
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measurement and 40 and 270 breathsmin−1 after morphine or fenta-
nyl treatment.
Respiratory time course data from the United Kingdom and
Australia were normalised to the pre-drug baseline as 100%. Data are
presented as percentage change from the pre-drug baseline, calcu-
lated for each mouse individually before mean data were plotted. Pre-
senting data as percentage change from the pre-drug levels has been
done to control for variation between treatment groups that may
have different baseline levels of respiration. Normal distribution of
the data was verified before performing parametric statistical analysis.
Wherever appropriate, data were analysed using one-way or two-way
ANOVA, followed by Bonferroni's post hoc tests. Statistical
significance is assumed when P <0.05. All calculations were performed
using GraphPad Prism 5, 6, or 7 software (GraphPad Software, Inc.,
San Diego, CA, RRID:SCR_002798). The data and statistical
analysis comply with the recommendations of the British Journal of
Pharmacology on experimental design and analysis in pharmacology
(Curtis et al., 2015).
2.7 | Data availability
The authors declare that all data supporting the findings of this study
are presented within the paper and its supporting information files.
The data that support the findings of this study are available from the
authors upon reasonable request.
2.8 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to PHARMA-
COLOGY (Harding et al., 2018), and are permanently archived in the
Concise Guide to PHARMACOLOGY 2019/20 (Alexander et al.,
2019).
3 | RESULTS
In our studies, we utilised the same β-arrestin2 knockout mouse line
that was used in the initial study (Raehal et al., 2005). We backcrossed
our β-arrestin2 knockout mice over four to seven generations to wild-
type control C57BL/6J mice. The absence of β-arrestin2 protein
expression was confirmed for the mice used in each laboratory by
western blotting and genotyping (Figures 1e and S2). We also con-
firmed that β-arrestin1 protein expression is unchanged in brains of β-
arrestin2 knockout mice (Figure S1). Whole-body plethysmography
(Buxco/DSI Instruments) performed in Sydney, Australia, clearly
showed a dose-dependent depression of respiratory rate by morphine
(6–100 mgkg−1 s.c.) in both β-arrestin2 knockout and wild-type mice
which persisted for over 3 hr following drug injection (Figure 1a). The
predominant effect of morphine on respiration in mice is a depression
of rate rather than depth of breathing (Hill et al., 2016). Similar results
were obtained with a nose-out plethysmography system (Harvard
Apparatus) in Jena, Germany (Figure 1c). Respiratory rate was signifi-
cantly reduced in both β-arrestin2-deficient and wild-type mice after
administration of morphine (3.75–52.5 mgkg−1 s.c.; Figure 1c).
Whole-body plethysmography (EMKA Technologies) studies per-
formed in Bristol, UK, also observed an equal, dose-dependent
depression of respiration by morphine (3–30 mgkg−1 i.p.; Figure 1b)
in both β-arrestin2 knockout and wild-type mice. Thus, three indepen-
dent studies of respiratory depression by morphine using different
plethysmography systems and data evaluations on independently bred
transgenic mice have failed to find evidence that β-arrestin2 signalling
is involved in opioid-induced respiratory depression (Figure 1f).
Fentanyl is a potent μ-opioid agonist responsible for a large num-
ber of overdose deaths amongst drug users in North America
(Lyden & Binswanger, 2019). The group which first reported that mor-
phine did not induce respiratory depression in β-arrestin2 knockout
mice have recently suggested that fentanyl is β-arrestin signalling
biased and that this explains its propensity for causing severe respira-
tory depression (Schmid et al., 2017). We (the Jena group) therefore
examined the ability of fentanyl to depress respiration in β-arrestin2
knockout mice. Fentanyl (0.05–0.35 mgkg−1 s.c.) produced a compa-
rable depression of respiratory rate in both wild-type and β-arrestin2
knockout mice (Figure 1d).
Like respiratory depression, constipation is another classical μ-
opioid receptor-mediated side effect. Quantification of accumulated
faecal boli over a broad dose ranges of morphine and fentanyl showed
profound constipation without significant difference between geno-
types (Figure 2).
4 | DISCUSSION
Biased agonism has been proposed as a means to separate desirable
from adverse drug responses downstream of a GPCR target.
However, for the μ-opioid receptor, the biased agonism concept has
two major weaknesses. First, it is predicated on a single study on
β-arrestin2 knockout mice that has never been reproduced in another
laboratory. Second, the molecular pathways leading from β-arrestin2
recruitment to respiratory depression in vivo have not been
delineated. The finding of substantially reduced morphine-induced
respiratory depression in the β-arrestin2 knockout mouse, reported by
Raehal et al. (2005), is a central pillar of the notion that G protein bias
drives opioid safety. However, the present study as tested in multiple
laboratories independently failed to reproduce this phenotype.
At this time, we are unable to explain why our results contradict
those originally published. The publication by Raehal et al. (2005) did
not specify the background of mice or number of generations of
inbreeding or back-crossing that had been performed at that stage.
The original study reporting the generation of the β-arrestin2 knock-
out mouse and a phenotype of increased sensitivity to morphine
antinociception was performed on a mixed C57BL/6 and 129SvJ
background. Genetic analysis performed by the The Jackson
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F IGURE 1 Respiratory depressant effect of morphine in β-arrestin2 knockout mice. (a) Data: Sydney, Australia. Time course of respiratory
rate depression following injection of 6, 10, or 50 mgkg−1 of morphine s.c. measured with whole-body plethysmography chambers (Buxco/DSI
Instruments; n = 6–11). Parameters were normalised to the pre-drug baseline as 100%. For dose–response curves, maximum depression of
respiratory rate data from experiments in which mice were injected with 3–100 mgkg−1 were fitted to a logistic function. (b) Data: Bristol, United
Kingdom. Depression of respiratory rate following injection of 3, 10, and 30 mgkg−1 morphine i.p. injection presented as respiratory rate (n = 6)
measured with whole-body plethysmography chambers (EMKA Technologies). The percentage respiratory rate following morphine injection for
each animal was normalised to the pre-drug baseline as 100%; baseline respiration rates before morphine injection in mice breathing 5% CO2 in
air were 472.2 ± 23.7 and 484.5 ± 16.1 in wild-type (WT) and β-arrestin2 knockout mice, respectively (n = 6). Data are the means ± SEM. (c) Data:
Jena, Germany. Time course of respiratory rate measured with a nose-out plethysmography system (Harvard Apparatus) 30 min after 3.5, 15, or
52.5 mgkg−1 of morphine s.c. (n = 6). Furthermore, dose–response curves of mean respiratory suppression over 30 min in which mice were
injected with 3.5–52.5 mgkg−1 are reported as the means ± SEM; baseline were set as 0. In (a)–(c), there was no statistical difference between
morphine respiratory depression in β-arrestin2 knockout and WT mice as determined by two-way ANOVA with Bonferroni post hoc test.
(d) Data: Jena, Germany. Time course of respiratory rate in WT and β-arrestin2 knockout mice measured with nose-out plethysmography system
15 min after 0.05, 0.1 or 0.3 mgkg−1 of fentanyl s.c. (n = 6). Dose–response curves of respiratory suppression over 30 min in which mice were
injected with 0.05–0.3 mgkg−1 are reported as the means ± SEM; baselines were set as 0. Two-way ANOVA with Bonferroni post hoc test.
(e) Brain lysates from WT and β-arrestin2 knockout mice (n = 2) were analysed for expression of β-arrestin2. Blots were stripped and probed with
anti-actin antibody to confirm equal loading. The positions of molecular mass markers are indicated on the left (in kDa). (f) Schematic drawing of
intracellular signalling cascades postulating that opioid-induced respiratory depression is mediated by G protein signalling
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Laboratory suggested that these mice may have been backcrossed to
C57BL/6 for fewer than the reported 10 generations prior to arrival
(https://www.jax.org/strain/011130). In fact, Raehal et al. (2005)
acknowledged in their Methods that they had in some experiments
used first-generation offspring. Thus, we may speculate that the initial
study was performed in part on a mixed C57BL/6 and 129SvJ back-
ground, which may provide one possible explanation for the differ-
ences between our study and the initial study. Indeed, at the recent
2019 International Narcotics Research Conference, it was reported by
another group, led by Jennifer Whistler, that they too could not repro-
duce opioid respiratory depression in β-arrestin2 knockout mice and
also that 129SvJ mice showed little respiratory depression in response
to morphine (Whistler, personal communication).
There is evidence for μ-opioid receptor-mediated respiratory
depression being the result of G protein signalling through Gi/Go
protein-activated inwardly rectifying potassium channel (GIRK) activa-
tion. μ-Opioid receptor activation by DAMGO or fentanyl leads to
inhibition of rhythmic breathing (Montandon et al., 2016). Mice lac-
king the GIRK2 protein, an integral subunit of neuronal GIRK chan-
nels, did not show respiratory depression after systemic fentanyl or
local DAMGO administered in the ventrolateral medulla. Furthermore,
in wild-type mice, direct inhibition of GIRK channels by local adminis-
tration of Tertiapin-Q markedly reduced DAMGO depression of respi-
ration. Additional evidence showed that opioid-induced, GIRK-
mediated hyperpolarisation of neurons in a distinct respiratory centre
reduced respiratory rate (Kliewer et al., 2019; Levitt, Abdala, Paton,
Bissonnette, & Williams, 2015). These results indicate that μ-opioid
receptor Gi/Go signalling through GIRK channels plays a pivotal role in
opioid-induced respiratory depression. The role of μ-opioid receptor
Gi/Go signalling through calcium channel inhibition has not been
investigated to date.
Schmid et al. (2017) have proposed that fentanyl's ability to
depress respiration results from it being an “arrestin-biased” μ-
opioid receptor agonist (i.e. it is better at recruiting and signalling
through arrestin than activating G protein signalling) and that
opioid depression of respiration is mediated by arrestin signalling
as proposed by Raehal et al. (2005). There are however two prob-
lems with their assertion. First, close inspection of their data
reveals that fentanyl only showed arrestin bias when comparing
arrestin recruitment with GTPyS binding. Fentanyl did not exhibit
bias when comparing arrestin recruitment with inhibition of cAMP
accumulation despite μ-opioid receptor inhibition of cAMP accumu-
lation being G protein mediated. Furthermore, we have previously
reported that in our hands fentanyl does not exhibit arrestin bias
in arrestin translocation and GTPyS binding assays (McPherson
et al., 2010; Rivero et al., 2012). Apparent bias may be a conse-
quence of the experimental protocol and in vitro assay system
utilised (Thompson et al., 2016). Thus, care should be taken when
extrapolating in vitro profiles to link a specific receptor signalling
process to a behavioural response.
Second, in transgenic mice in which all the phosphorylation sites
on the C-tail of the μ-opioid receptor had been mutated to alanine,
fentanyl still depressed respiration (Kliewer et al., 2019). In these
transgenic mice, μ-opioid receptors are not phosphorylated by G pro-
tein receptor kinases and thus do not bind arrestins. This observation
brings into question the concept that opioid depression of respiration
is a function of arrestin signalling (Montandon & Slutsky, 2019). We
have reported that PZM21, a purportedly G protein-biased ligand,
depresses respiration in mice (Hill et al., 2018) despite an initial report
to the contrary (Manglik et al., 2016).
Together, this collaborative study unequivocally demonstrates
the persistence of opioid-induced respiratory depression in
β-arrestin2 knockout mice. This is in line with our recently reported
finding that knock-in of phosphorylation-deficient μ-opioid
receptors that cannot recruit arrestins does not improve opioid
safety (Kliewer et al., 2019). Both sets of results bring into
question the concept of developing drugs that activate G
proteins better than they recruit arrestins (i.e. “G protein-biased
agonists”), as a strategy for the development of safer opioid anal-
gesic drugs.
F IGURE 2 Opioid-induced
constipation in β-arrestin2 knockout mice.
Dose–response curves for accumulated
faecal boli weight in the constipation test
after (a) morphine and (b) fentanyl
administration (n = 6–18). Data are the
means ± SEM; *indicate statistically
significant differences between drug and
vehicle; n.s. indicates no statistically
significant differences between
genotypes; one-way ANOVA with
Bonferroni post hoc test. Data from Jena,
Germany
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